Sign In
Buy PPRUY
Kering SA Earnings Calls
| Release date | Feb 10, 2026 |
| EPS estimate | $0.283 |
| EPS actual | $0.147 |
| EPS Surprise | -48.27% |
| Revenue estimate | 8.559B |
| Revenue actual | 8.201B |
| Revenue Surprise | -4.18% |
| Release date | Jun 30, 2025 |
| EPS estimate | $0.403 |
| EPS actual | $0.455 |
| EPS Surprise | 12.88% |
| Revenue estimate | 8.899B |
| Revenue actual | 8.933B |
| Revenue Surprise | 0.381% |
| Release date | Apr 25, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Dec 31, 2024 |
| EPS estimate | $0.330 |
| EPS actual | $0.215 |
| EPS Surprise | -34.68% |
| Revenue estimate | 8.376B |
| Revenue actual | 8.466B |
| Revenue Surprise | 1.08% |
Last 4 Quarters for Kering SA
Below you can see how PPRUY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Dec 31, 2024 |
| Price on release | $24.63 |
| EPS estimate | $0.330 |
| EPS actual | $0.215 |
| EPS surprise | -34.68% |
| Date | Price |
|---|---|
| Dec 24, 2024 | $24.61 |
| Dec 26, 2024 | $24.69 |
| Dec 27, 2024 | $24.71 |
| Dec 30, 2024 | $24.59 |
| Dec 31, 2024 | $24.63 |
| Jan 02, 2025 | $23.99 |
| Jan 03, 2025 | $23.08 |
| Jan 06, 2025 | $23.67 |
| Jan 07, 2025 | $23.85 |
| 4 days before | 0.0813% |
| 4 days after | -3.17% |
| On release day | -2.60% |
| Change in period | -3.09% |
| Release date | Apr 25, 2025 |
| Price on release | $19.91 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Apr 21, 2025 | $18.51 |
| Apr 22, 2025 | $19.48 |
| Apr 23, 2025 | $19.03 |
| Apr 24, 2025 | $19.79 |
| Apr 25, 2025 | $19.91 |
| Apr 28, 2025 | $20.40 |
| Apr 29, 2025 | $20.36 |
| Apr 30, 2025 | $20.07 |
| May 01, 2025 | $20.22 |
| 4 days before | 7.56% |
| 4 days after | 1.56% |
| On release day | 2.41% |
| Change in period | 9.24% |
| Release date | Jun 30, 2025 |
| Price on release | $21.82 |
| EPS estimate | $0.403 |
| EPS actual | $0.455 |
| EPS surprise | 12.88% |
| Date | Price |
|---|---|
| Jun 24, 2025 | $21.03 |
| Jun 25, 2025 | $20.59 |
| Jun 26, 2025 | $20.54 |
| Jun 27, 2025 | $21.64 |
| Jun 30, 2025 | $21.82 |
| Jul 01, 2025 | $22.98 |
| Jul 02, 2025 | $23.95 |
| Jul 03, 2025 | $23.30 |
| Jul 07, 2025 | $22.81 |
| 4 days before | 3.76% |
| 4 days after | 4.54% |
| On release day | 5.32% |
| Change in period | 8.46% |
| Release date | Feb 10, 2026 |
| Price on release | $34.01 |
| EPS estimate | $0.283 |
| EPS actual | $0.147 |
| EPS surprise | -48.27% |
| Date | Price |
|---|---|
| Feb 04, 2026 | $31.18 |
| Feb 05, 2026 | $30.58 |
| Feb 06, 2026 | $30.62 |
| Feb 09, 2026 | $30.91 |
| Feb 10, 2026 | $34.01 |
| Feb 11, 2026 | $33.68 |
| Feb 12, 2026 | $33.30 |
| Feb 13, 2026 | $33.78 |
| Feb 17, 2026 | $32.44 |
| 4 days before | 9.08% |
| 4 days after | -4.62% |
| On release day | -0.97% |
| Change in period | 4.04% |
Kering SA Earnings Call Transcript Summary of Q4 2025
Kering reported a challenging 2025 that management characterizes as a trough and a turning point. Group revenue (ex-Kering Beauté) was €14.7bn, down 10% comparable, with sequential improvement through the year and Q4 at -3% comparable. Recurring operating income was €1.6bn (11.1% EBIT margin), down 33% y/y, helped by €925m of cost savings and 75 net store closures in 2025 (with a further 100 net closures planned in 2026). Free cash flow was €4.4bn including real estate transactions (€2.3bn excluding real estate); net debt fell €2.5bn to €8.0bn and will be further reduced by the planned sale of Kering Beauté to L’Oréal (closing H1 2026, ~€4bn inflow). Management expects 2026 to be a year of construction and gradual return to growth and margin improvement across the portfolio, driven by renewed creative leadership, tighter retail footprint, operational discipline, investment in desirability (product and above-the-line marketing), and platform-level efficiencies (industrial, supply chain, tech/AI). Notable portfolio moves: partnership with L’Oréal for beauty and progressive acquisition of Raselli to strengthen jewelry capabilities. Brand-level: Gucci remains the largest challenge but showed early signs of stabilization (Q4 improvement and product initiatives like La Famiglia); Saint Laurent and Bottega are in stronger positions; Balenciaga and Alexander McQueen require further work (McQueen restructuring underway). Capital allocation: Board proposes ordinary dividend €3/share plus exceptional €1/share related to the Beauté disposal; leverage is expected to fall materially post-closing, with pro-forma leverage in a comfortable investment-grade range. A Capital Markets Day on April 16 will present the detailed strategy and roadmap.
